Martín
Lazaro Quintela
Complexo Hospitalario Universitario de Ourense
Orense, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario de Ourense (15)
2024
2022
-
Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
Lung Cancer, Vol. 173, pp. 83-93
-
Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group
Cancer Treatment and Research Communications, Vol. 33
2021
-
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group
Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415
-
Electronic health records and patient registries in medical oncology departments in Spain
Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108
-
Preferences for Renal Cell Carcinoma Pharmacological Treatment: A Discrete Choice Experiment in Patients and Oncologists
Frontiers in Oncology, Vol. 11
-
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study
ESMO open, Vol. 6, Núm. 2, pp. 100090
2020
-
Latest progress in molecular biology and treatment in genitourinary tumours
Clinical and Translational Oncology, Vol. 22, Núm. 12, pp. 2175-2195
2019
-
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Clinical and Translational Oncology, Vol. 21, Núm. 3, pp. 249-258
2018
-
Abordaje del paciente con cáncer renal: ¿existe la colaboración entre urología y oncología?
Actas Urologicas Espanolas
-
Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group
Clinical and Translational Oncology, Vol. 20, Núm. 11, pp. 1467-1473
2015
-
Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors
Journal of Analytical Oncology, Vol. 4, Núm. 3, pp. 94-101
2014
-
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: Review of patient profile
Anti-Cancer Drugs, Vol. 25, Núm. 4, pp. 368-374
2012
-
First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients
Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396
2009
-
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384